Stay updated with the latest placebo news, articles, and insights from trusted sources. Explore in-depth coverage and expert analysis on placebo topics.
Raichur (Karnataka) [India], August 14: In a landmark moment for global hepatology and Indian pharmaceutical innovation, Shilpa Medicare Limited (BSE: 530661) (NSE: SHILPAMED) has secured the world first regulatory approval from India Central Drugs Standard Control Organization (CDSCO) for Nor Ursodeoxycholic Acid (NorUDCA) Tablets 500 mg, the first-ever approved therapy targeting NAFLD. * Shilpa Medicare emerges as the global pioneer to receive approval for NorUDCA, offering new hope to over a ...Read More >
Raichur (Karnataka) [India], August 14: In a landmark moment for global hepatology and Indian pharmaceutical innovation, Shilpa Medicare Limited (BSE: 530661) (NSE: SHILPAMED) has secured the world's first regulatory approval from India's Central Drugs Standard Control Organization (CDSCO) for Nor Ursodeoxycholic Acid (NorUDCA) Tablets 500 mg, the first-ever approved therapy targeting NAFLD. Also Read | 'Coolie' X Review: Rajinikanth's 'One-Man Show' With Nagarjuna's Stylish Act and Anirudh Rav ...Read More >
Raichur (Karnataka) [India], August 14: In a landmark moment for global hepatology and Indian pharmaceutical innovation, Shilpa Medicare Limited (BSE: 530661) (NSE: SHILPAMED) has secured the world first regulatory approval from India Central Drugs Standard Control Organization (CDSCO) for Nor Ursodeoxycholic Acid (NorUDCA) Tablets 500 mg, the first-ever approved therapy targeting NAFLD. * Shilpa Medicare emerges as the global pioneer to receive approval for NorUDCA, offering new hope to over a ...Read More >
New Delhi: Enrolment of about 10,500 participants in the phase III clinical trial of the indigenous one-shot Panacea Biotec developed dengue vaccine, DengiAll, is likely to be completed by October across 20 centres in India, according to ICMR scientists. So far, 8,000 participants in various centres at Pune, Chennai, Kolkata, Delhi and Bhubaneswar, among others, have received either the vaccine or a placebo as part of the trial sponsored by the Indian Council of Medical Research (ICMR) and Pana ...Read More >
Representative Image: Currently, there is no antiviral treatment or licensed vaccine against dengue in India | Image: Bloomberg Enrolment of about 10,500 participants in the phase III clinical trial of the indigenous one-shot Panacea Biotec developed dengue vaccine, DengiAll, is likely to be completed by October across 20 centres in India, according to ICMR scientists. So far, 8,000 participants in various centres at Pune, Chennai, Kolkata, Delhi and Bhubaneswar among others have received eith ...Read More >
New Delhi, Jul 3 (PTI) Adopting a healthier lifestyle is more effective than using the anti-diabetes drug metformin, with the benefits persisting over 20 years later, according to a study. The US Diabetes Prevention Program, launched in 1996, enrolled 3,234 patients with prediabetes from 30 institutions across 22 states. The study aimed to compare the benefits of metformin and a lifestyle modification that included exercise and a healthy diet. Also Read | RBI Bank Holiday List for July 2025: B ...Read More >
New Delhi, Jul 3 (PTI) Adopting a healthier lifestyle is more effective than using the anti-diabetes drug metformin, with the benefits persisting over 20 years later, according to a study. The US Diabetes Prevention Program, launched in 1996, enrolled 3,234 patients with prediabetes from 30 institutions across 22 states. The study aimed to compare the benefits of metformin and a lifestyle modification that included exercise and a healthy diet. Researchers from The University of New Mexico, US, ...Read More >
Stay updated with the latest None news, articles, and insights from trusted sources. Explore in-depth coverage and expert analysis on None topics.